CYLD is a 956 aa, cytoplasmic, deubiquitinating enzyme belonging to the ubiquitin carboxy-terminal hydrolases (UCH) family of proteins with three cytoskeletal-associated protein-glycine-conserved (CAP-GLY) domains, a proline rich region, a SH3 binding domain and a sequence homology to catalytic domain of UCH.
CYLD is identified as a tumor suppressor protein affecting the JNK signaling pathway.
CYLD is a negative regulator of TRAF2 and NF-kappa-B signaling pathway and is also known to have receptor-dependent role in regulating the I-kappa-B kinase pathway.
It also has a deubiquitinating activity that is directed towards non-Lys-48-linked polyubiquitin chains and TRAP1 is a novel substrate for deubiquitination.
Mutated CYLD is known to be associated with cylindromatosis, multiple familial trichoepithelioma, and Brooke-Spiegler syndrome.
Applications:Suitable for use in Western Blot, Immunofluorescence and Immunocytochemistry.
Other applications not tested.
Recommended Dilution:Western Blot: 2-4ug/mlSimple Western: 1:50Immunocytochemistry/Immunofluorescence: 5-10ug/mlOptimal dilutions to be determined by the researcher.
Storage and Stability:May be stored at 4°C for short-term only.
Aliquot to avoid repeated freezing and thawing.
Store at -20°C.
Aliquots are stable for 12 months after receipt.
For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
仕様
Size：100ug
Host：rabbit
Source Antibody：human
Grade：Affinity Purified
Purity：Purified by Protein G affinity chromatography.
Form：Supplied as a liquid in PBS, 0.05% sodium azide.
Specificity：Recognizes human CYLD.
Isotype：IgG
Calc Applications Abbrev：IC IF WB
Calc Crossreactivity：Hu
Immunogen：Synthetic peptide (DKQTQKLLKVPKGS) corresponding to amino acids 32-45 of human CYLD. Species sequence homology: mouse, rat, primate, feline and bovine
